ethambutol (myambutol) Report issue

Small molecule Approved FDA Priority Review FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
ETHAMBUTOL HYDROCHLORIDE is an oral chemotherapeutic agent which is specifically effective against actively growing microorganisms of the genus Mycobacterium, including M. tuberculosis. Ethambutol inhibits RNA synthesis and decreases tubercle bacilli replication. Nearly all strains of M. tuberculosis and M. kansasii as well as a number of strains of MAC are sensitive to ethambutol. Ethambutol inhibits arabinosyl transferases which is involved in cell wall biosynthesis. By inhibiting this enzyme, the bacterial cell wall complex production is inhibited. This leads to an increase in cell wall permeability. ETHAMBUTOL HCl is indicated for the treatment of pulmonary tuberculosis. It should not be used as the sole antituberculous drug, but should be used in conjunction with at least one other antituberculous drug.   NCATS

Chemistry

More Chemistry

Pharmacology

Drug Pricing (per unit)

United States

$0.1324 - $4.3610
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

(+)-2,2'-(ethylenediimino)di-1-butanol | (2s,7s)-2,7-diethyl-3,6-diazaoctane-1,8-diol | cl-40881 | diambutol | emb | etambutol | etambutolo | ethambutol | (+)-ethambutol | ethambutol dihydrochloride | ethambutol hcl | ethambutol hydrochloride | ethambutolum | myambutol | mynah 200 | mynah 250 | mynah 300 | mynah 365 | (+)-n,n'-bis(1-(hydroxymethyl)propyl)ethylenediamine | (+)-s,s-ethambutol | (s,s)-ethambutol | s,s-ethambutol

Organizations (223)

Research & Development (218)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (5)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (19)

Approved Indications (2)


 

Tuberculosis

Tuberculosis, Pulmonary

Experimental Indications - Clinical Trial Phases 1-4 (19)


 

Acquired Immunodeficiency Syndrome (Phase 4)

Extensively Drug-Resistant Tuberculosis (Phase 3)

Healthy Volunteers (Phase 1)

HIV (Phase 3)

HIV Infections (Phase 4)

Lung Diseases (Phase 4)

Mycobacterium avium Complex (Phase 3)

Mycobacterium avium-intracellulare Infection (Phase 4)

Mycobacterium Infections, Nontuberculous (Phase 4)

Obesity (Phase 4)

Respiratory Tract Infections (Phase 4)

Sarcoidosis (Phase 2)

Sarcoidosis, Pulmonary (Phase 1)

Tuberculosis (Phase 4)

Tuberculosis, Meningeal (Phase 3)

Tuberculosis, Multidrug-Resistant (Phase 3)

Tuberculosis, Pulmonary (Phase 4)

Tuberculosis, Spinal (Phase 4)

Uveitis, Anterior (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 99
  • # of Trial Organizations: 218

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue